Martin J. van den Bent, MD, &lrm;Head Neuro-Oncology Unit at Erasmus MC Cancer Center, discusses what the next trials will be for ABT-414, anti-EGFR antibody-drug conjugate under exploration for patients with brain cancer.

In an expansion cohort of a phase I study, patients with EGFR-amplified, recurrent glioblastoma (GBM) who were treated with ABT-414 experienced a 6-month progression-free survival (PFS) rate of 35%. While this trial was a phase I expansion trial, van den Bent notes, the results proved that further investigation was warranted.

There is currently an ongoing phase II trial exploring ABT-414 alone or with temozolomide in comparison with lomustine or temozolomide for patients with recurrent GBM. This study will include a pediatric arm focused on adverse events (NCT02343406). The primary endpoints for the adult arm of the study, which is known as INTELLANCE 2, are PFS and overall survival (OS).

Additionally, a phase II study is exploring the frontline use of ABT-414 for patients with newly-diagnosed GBM (NCT02573324). This trial, INTELLANCE 1, has dual primary endpoints of PFS and OS.

These studies will provide more data to understand which patients respond well to ABT-414 and which would be resistant to the compound, van den Bent noted.

View more from the 2016 SNO Annual Meeting

Martin van den Bent, MD, PhD

Articles

Dr. van den Bent on Next Steps for ABT-414 in Brain Cancer